A natural plant compound best known as chamomile's calming ingredient, taken for sleep, calm, and long-term cellular health. Its gentle sleep and anxiety benefits are modestly supported; metabolic and longevity claims rest mainly on animal data and are limited by poor absorption. Inexpensive and well tolerated, though it may affect medication levels. (Full Review)

Protocol

Dose

~50 mg

Most widely used amount; reflects the sleep/calming use rather than a validated longevity dose

Timing

Before bed

About 30–60 minutes before bed; evening preferred because of the mild sedative effect

Frequency

Once daily

Long, variable elimination (~12 h or more) makes once-daily evening dosing typical

Time to effect

Sleep & calm

30–60 min

Acute calming/sleep effect felt within about 30–60 minutes of an evening dose

Metabolic

Weeks

Any anti-inflammatory or metabolic effects build over weeks and are subtle

Longevity

Months+

Not perceptible; could only be inferred from biomarkers over months

Benefits

Medium: Sleep quality and reduced anxiety

Low: Blood sugar and lipid regulation; systemic inflammation reduction

Speculative: NAD+ preservation and longevity signaling; cancer risk reduction; cognitive and neuroprotective effects

Contraindications

Pregnancy or breastfeeding

Hormone-sensitive cancers or conditions

Warfarin use or bleeding disorders

Surgery within about 2 weeks

Chamomile, ragweed, or other Asteraceae-family allergy

Key Interactions

Blood thinners and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)

CYP3A4 substrates (simvastatin, certain calcium-channel blockers, some immunosuppressants)

CYP1A2 and CYP2C9 substrates (theophylline, some NSAIDs, phenytoin)

Sedatives and CNS depressants (benzodiazepines, Z-drugs, opioids, antihistamines, alcohol)

Over-the-counter NSAIDs (ibuprofen, naproxen)

Blood-sugar-lowering drugs (metformin, sulfonylureas, insulin)

Calming supplements (valerian, magnesium, L-Theanine, melatonin); grapefruit and flavonoid extracts

Risk & Side Effects

Low: Cytochrome P450 and drug-metabolism interference; estrogen-pathway modulation; additive sedation and drowsiness

Speculative: Bleeding potentiation; allergic reactions; high-dose and pregnancy-related effects

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation, apigenin's proposed target
Fasting glucose	70–90 mg/dL	Gauges blood-sugar effect for metabolic users
HbA1c	< 5.4%	Reflects average blood sugar over ~3 months
Fasting lipid panel	Triglycerides < 80 mg/dL; HDL > 50 mg/dL	Captures the lipid changes seen in chamomile trials
ALT / AST	< 25 U/L	Safety check at higher doses given hepatic metabolism
Estradiol	Sex- and age-appropriate range	Contextualizes apigenin's estrogen-pathway activity

Cadence: Baseline before use; re-check relevant markers at about 3 months, then every 6–12 months

Qualitative Assessment

Sleep quality and time to fall asleep
Daytime calm versus residual grogginess
Anxiety and stress levels
Energy and general wellbeing

Apigenin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment